+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.

Age: 55Years - 90YearsAll GendersPhase 3
296 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in treating cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to improve thinking abilities measured by specific standardized assessments. Participants will receive either KarXT plus KarX-EC or a placebo at specified doses on designated days. The study lasts 24 weeks, during which outcomes like changes in cognitive function, daily living activities, and behavioral symptoms will be assessed. The trial includes an active comparison group and a placebo group to evaluate treatment effects. Throughout the study, participants and their caregivers will attend regular visits for clinical assessments, including cognitive tests ADAS-Cog11, caregiver interviews, and monitoring of adverse events and vital signs. Researchers will carefully track safety and treatment response over the 24-week period to understand the impact of the study drugs on Alzheimers symptoms.

Age: 60Years - 85YearsAll GendersPhase 3
128 locations
E

Actively Recruiting

Researchers are evaluating the safety and effects of a study medicine called PF-07328948 for treating adults with heart failure. This phase 2 clinical trial compares PF-07328948 to a placebo in people who are already receiving standard heart failure treatments, including sodium-glucose cotransporter 2 SGLT2 inhibitors. The study aims to determine if PF-07328948 is safe and effective for heart failure patients with specific symptoms and heart function measurements. Participants will take either PF-07328948 tablets or placebo tablets once daily by mouth for 36 weeks. There are four groups placebo, low dose, medium dose, and high dose of PF-07328948. The trial uses a randomized, double-blind design. During the study, participants will continue their regular heart failure medications alongside the study drug or placebo. Participants will be involved for about 48 weeks, including 36 weeks of treatment and follow-up. They will have 15 visits to the study clinic, with 10 visits in person and 5 conducted at home by phone. Assessments include clinical event tracking, 6-minute walk tests, and questionnaires to evaluate symptoms and physical limitations. Safety monitoring and health status questionnaires will be performed throughout the study.

Age: 18Years - 79YearsAll GendersPhase 2
150 locations
R

Actively Recruiting

Researchers are evaluating the overall survival of patients with stage I epithelial ovarian cancer after they have undergone comprehensive staging surgery. This phase III trial compares the outcomes of adjuvant chemotherapy versus observation alone. The study aims to determine whether adding chemotherapy after surgery improves survival in this patient group. Participants will be randomly assigned to one of two groups. One group receives adjuvant chemotherapy, which includes either a combination of paclitaxel and carboplatin or docetaxel and carboplatin, given every three weeks for three to six cycles. Switching between paclitaxel and docetaxel is allowed if adverse events occur. The other group undergoes observation without chemotherapy. During the study, participants will be monitored for overall survival up to 60 months from randomization. Researchers will also assess relapse-free survival within the same timeframe. Evaluations include follow-ups to track disease progression, side effects, and general health. The study ensures participants receive appropriate care and measures outcomes to better understand treatment benefits and risks.

Age: 20Years +FEMALEPhase 3
103 locations